📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Neuland Labs Q3FY26 Revenue Up 11.4% to ₹447.8 Cr; EBITDA Margin Dips to 19%
Neuland Laboratories reported an 11.4% YoY increase in total income to INR 447.8 crores for Q3FY26, with the CMS (CDMO) segment contributing over 50% of revenue. EBITDA margins compressed to 19% from previous highs, primarily due to a shift in product mix and a one-time INR 10 crore impact from labor codes. Despite a significant 9-month capex of INR 254 crores, the company maintains a strong net cash position of INR 202.6 crores. Management noted that the absence of a specific high-margin CMS product shipment and delays in Paliperidone contributed to the quarterly margin dip.
Key Highlights
Total income grew 11.4% YoY to INR 447.8 crores, driven by commercial CMS projects.
EBITDA margin stood at 19%; adjusted for a INR 10 crore labor code impact, the margin would be 21%.
9-month gross margin remains healthy at 56% compared to 55% in the previous year.
Significant 9-month capex of INR 254 crores funded largely through internal accruals and customer advances.
Working capital cycle stretched to 145 days due to higher inventories and uneven delivery flows.
💼 Action for Investors
Investors should look past the quarterly margin volatility and focus on the successful ramp-up of expanded CMS capacity in Unit 3. The company's transition toward complex molecules and peptides remains the primary long-term value driver.
Neuland Labs Q3FY26 Results: PAT Drops 60.2% YoY to Rs 40.4 Cr as Margins Contract
Neuland Laboratories reported a challenging Q3FY26 with a significant 60.2% YoY decline in Profit After Tax (PAT) to Rs 40.4 crore. While Total Income grew 11.4% YoY to Rs 447.8 crore, it fell 13.2% on a sequential basis. The company faced severe margin pressure, with EBITDA margins contracting to 19.0% from 30.4% in the previous quarter, driven by an unfavorable product mix and higher operating expenses. Management remains focused on long-term investments despite the current subdued profitability.
Key Highlights
Total Income for Q3FY26 reached Rs 447.8 crore, up 11.4% YoY but down 13.2% QoQ.
EBITDA fell 5.9% YoY and 45.8% QoQ to Rs 85.0 crore.
EBITDA margins contracted sharply to 19.0%, down from 22.5% YoY and 30.4% QoQ.
Profit After Tax (PAT) plummeted 60.2% YoY to Rs 40.4 crore compared to Rs 101.4 crore in Q3FY25.
Management cited product mix shifts and increased operating expenses as primary reasons for subdued margins.
💼 Action for Investors
Investors should exercise caution due to the sharp sequential decline in margins and profitability. It is essential to monitor management's guidance on the recovery of the product mix and the impact of ongoing investments on future earnings.
Neuland Labs Q3FY26: Revenue Grows 11% YoY, but PAT Declines 60% on Margin Pressure
Neuland Laboratories reported a mixed Q3FY26 with total income rising 11.4% YoY to ₹447.8 crore, supported by growth in the CMS and Prime segments. However, EBITDA margins contracted significantly by 350 bps to 19.0% due to an unfavorable product mix and higher operating expenses. Consequently, PAT for the quarter fell 60% YoY to ₹31.5 crore. Despite the bottom-line pressure, the company remains net debt-free with a cash surplus of ₹202.6 crore and continues to invest in R&D expansion.
Key Highlights
Total Income for Q3FY26 stood at ₹447.8 crore, up 11.4% YoY, while 9MFY26 income reached ₹1,264.4 crore.
EBITDA margin compressed to 19.0% in Q3FY26 from 22.5% in the previous year's quarter.
PAT for Q3FY26 dropped 60% YoY to ₹31.5 crore, with 9MFY26 PAT down 35% at ₹150.6 crore.
CMS segment remains robust with 98 active projects, including 19 commercial molecules and 10 in Phase-3.
Capital expenditure for 9MFY26 reached ₹254 crore, including plans for a new 140k sq. ft. R&D facility at Genome Valley.
💼 Action for Investors
Investors should be cautious regarding the sharp margin contraction and PAT decline, which may lead to short-term stock price volatility. Focus on the management's ability to improve the product mix and the long-term growth potential of the expanding CMS project pipeline.
Neuland Labs Q3 FY26 PAT Drops 60% YoY to ₹40.4 Cr; EBITDA Margins Contract to 19%
Neuland Laboratories reported a mixed Q3 FY26 with total income growing 11.4% YoY to ₹447.8 crore, but profitability faced significant pressure. EBITDA fell 5.9% YoY to ₹85 crore, with margins contracting sharply to 19.0% from 22.5% a year ago due to an unfavorable product mix and higher operating expenses. Net profit saw a steep decline of 60.2% YoY to ₹40.4 crore, though the previous year's base was higher due to exceptional items. Management remains optimistic about long-term growth driven by the NCE drug substance segment and niche capabilities despite the short-term margin volatility.
Key Highlights
Total Income grew 11.4% YoY to ₹447.8 crore but declined 13.2% on a sequential (QoQ) basis.
EBITDA margins contracted by 350 bps YoY and 1,140 bps QoQ to 19.0%.
Profit After Tax (PAT) plummeted 60.2% YoY to ₹40.4 crore from ₹101.4 crore in the previous year.
Management cited unfavorable product mix and increased operating expenses as primary reasons for margin compression.
9MFY26 Total Income reached ₹1,264.5 crore with cumulative EBITDA at ₹284 crore.
💼 Action for Investors
Investors should exercise caution due to the significant sequential margin compression and monitor the management's commentary on the sustainability of the current product mix. The stock may face short-term pressure until there is clarity on the recovery of EBITDA margins back toward the 25-30% range seen in previous quarters.
Neuland Labs Q3 PAT Drops 60% YoY to ₹40.57 Cr; Revenue Up 10.5% YoY
Neuland Laboratories reported a consolidated revenue of ₹439.71 crore for Q3 FY26, a 10.5% increase compared to ₹398.03 crore in the same quarter last year. However, Profit After Tax (PAT) saw a sharp decline of 60% YoY to ₹40.57 crore, down from ₹101.59 crore, partly due to a high base effect from an exceptional gain in the previous year. On a sequential basis, revenue fell 14.5% and PAT dropped 58% from Q2 FY26. Rising finance costs and manufacturing expenses further pressured margins during the quarter.
Key Highlights
Consolidated Revenue from Operations grew 10.5% YoY to ₹439.71 crore but declined 14.5% QoQ.
Net Profit (PAT) plummeted 60% YoY to ₹40.57 crore, impacted by higher operational costs and a lack of exceptional gains seen in the prior year.
Finance costs spiked to ₹6.79 crore compared to ₹2.22 crore in Q3 FY25, reflecting higher interest or debt obligations.
9M FY26 PAT stands at ₹151.33 crore, a 34.8% decrease from ₹232.30 crore in 9M FY25.
Geographically, USA and North America revenue grew to ₹191.80 crore, while India revenue saw a sharp decline to ₹91.59 crore from ₹172.07 crore in the previous quarter.
💼 Action for Investors
Investors should exercise caution as the company faces significant margin pressure and a sharp sequential slowdown in revenue. Monitor management's commentary regarding the spike in finance costs and the volatility in the India segment revenue.